VanEck Rare Earth/Strategic Metals vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? VanEck Rare Earth/Strategic Metals trades at $60.9 (market cap $1.75B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.78 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| REMX | SLS | |
|---|---|---|
Market Cap | $1.75B | $2.27B |
Volume | 930,523 | 4,179,659 |
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $15.46 |
52-Week Low | $60.58 | $1.39 |
Typical Hold Time | 50 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $61.00, down 1.42% with a bearish technical signal. The ETF shows extreme oversold conditions with RSI readings near 14, while ADX indicates a strong downtrend. Recent news highlights strategic importance of rare earth metals amid U.S. efforts to reduce dependence on China, though individual holdings like Critical Metals show volatile performance. Bank of America increased its position by 72.1% in the latest quarter, holding 427,651 shares as of August 2026.
The outlook remains challenged by high volatility and China export controls, but strategic positioning for supply chain independence offers long-term potential. Investors face significant price swings with 50% annualized volatility, requiring risk tolerance. The bearish technical setup suggests caution near-term despite oversold conditions.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →